Primary Prevention of Major Cardiovascular and Cerebrovascular Events with Statins in Diabetic Patients
- 675 Downloads
Patients with diabetes mellitus are at increased risk of developing cardiovascular disease. Controlling lipid levels has a preventive effect on the occurrence of major cardiovascular and cerebrovascular events. Individual trials have shown varying data on the efficacy of treatment with lipid-lowering statin therapy in the primary prevention of such events in diabetes.
The objective of this study was to assess the efficacy of statins in the primary prevention of the first-time occurrence of a major cardiovascular or cerebrovascular event in diabetic patients. Secondary endpoints were fatal/non-fatal stroke, fatal/non-fatal myocardial infarction and all-cause mortality.
A systematic search for trial reports was conducted in PubMed, EMBASE, The Cochrane library and clinicaltrials.gov for the years 1966–2011. Reference lists of reviews and meta-analyses of related subjects were searched. High-quality, randomized, double-blinded clinical trials comparing a statin with placebo for the primary prevention of major cardiovascular and cerebrovascular events in diabetic patients were selected. Only large studies with a minimum of 500 diabetic participants followed-up for at least 2 years were included. Endpoints were major cardiovascular and cerebrovascular events.
Trial and patient characteristics were extracted by three researchers. The quality of the included studies was tested with the Jadad score. The combined effect on primary as well as secondary endpoints was measured with a fixed-effect model. Publication bias was examined with a funnel plot.
Four trials were included, for a total of 10 187 participants. Treatment with statins in the primary prevention of major cardiovascular and cerebrovascular events in diabetic patients resulted in a significant relative risk (RR) reduction in the first-time occurrence of major cardiovascular or cerebrovascular events (RR 0.75, 95% CI 0.67–0.85), fatal/non-fatal stroke (RR 0.69, 95% CI 0.51–0.92) and fatal/non-fatal myocardial infarction (RR 0.70, 95% CI 0.54–0.90) and a non-significant RR reduction in all-cause mortality (RR 0.84, 95% CI 0.65–1.09). Among the studies there was non-significant heterogeneity in the individual effect estimates and no publication bias.
Exclusion criteria and endpoints varied slightly between studies. The type and dosing of statin therapy differed between studies. Non-compliance in the statin treatment group and the use of statin treatment in the placebo group could have led to lower risk reductions.
Treatment with statins in primary prevention among diabetic patients has a significant beneficial effect on event rates of the first-time occurrence of a major cardiovascular or cerebrovascular event, fatal/non-fatal stroke and fatal/non-fatal myocardial infarction. There was a non-significant RR reduction in all-cause mortality.
Unable to display preview. Download preview PDF.
- 1.World Health Organisation. Global health observatory: causes of death in 2008 [online]. Available from URL: http://www.who.int/gho/mortality_burden_disease/causes_death_2008/en/index.html [Accessed 2012 Jan 18]
- 2.American Heart Association. Cardiovascular disease and diabetes: statistics update 2010 [online]. Available from URL: http://www.heart.org/HEARTORG/Conditions/Diabetes/WhyDiabetesMatters/Cardiovascular-Disease-Diabetes_UCM_313865_Article.jsp [Accessed 2012 Jan 18]
- 6.Taylor F, Ward K, Moore TH, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 2011 Jan 19; (1): CD004816Google Scholar
- 8.Knopp RH, D’Emden M, Smilde JG, et al. Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin study for prevention of coronary heart disease endpoints in non-insulin-dependent diabetes mellitus (ASPEN). Diabetes Care 2006 Jul; 29(7): 1478–85PubMedCrossRefGoogle Scholar
- 15.Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004 Aug 21–27; 364: 685–96PubMedCrossRefGoogle Scholar
- 19.Review manager (RevMan) [computer program]. Version 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011Google Scholar
- 20.Borenstein M, Hedges LV, Higgins JPT, et al. Introduction to meta-analysis. Part 3 fixed-effect versus random effects models. Chichester: John Wiley & Sons, Ltd, 2009: 59–86Google Scholar
- 23.The ALLHAT officers and coordinators for the ALLHAT collaborative research group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT-LLT). JAMA 2002 Dec 18; 288(23): 2998–3007CrossRefGoogle Scholar
- 27.Grundy S, Cleeman JI, Merz NB, et al., for the Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials of the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation 2004 Jul 13; 100(2): 227–39CrossRefGoogle Scholar
- 28.Reiner Z, Catapano AL, De Backer G, et al. ESC/EAS guidelines for the management of dyslipidaemias. The task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011 Jul; 32(14): 1769–818PubMedCrossRefGoogle Scholar
- 29.Rutten GEHM, De Grauw WJC, Nijpels G. NHG-Standaard diabetes mellitus type 2. Huisarts Wet 2006; 49(3): 137–52Google Scholar
- 30.Wiersma TJ, Goudswaard AN. NHG-standard cardiovascular risk management [in Dutch]. Houten: Bohn Stafleu van Loghum, 2006Google Scholar